AstraZeneca Pharma India (NSE:ASTRAZEN) Other Stockholders Equity: ₹8,678 Mil (As of Mar. 2026)


NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
94 GF Score
Price ₹8,310.50
GF Value ₹10,925.42
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Other Stockholders Equity?

AstraZeneca Pharma India NSE:ASTRAZEN +0.83% 94 Other Stockholders Equity is ₹8,678 Mil as of Mar. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 94/100 and a GF Value™ of ₹10,925.42 (Modestly Undervalued). The stock has 4 warning signs investors should review.

AstraZeneca Pharma India's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹8,678 Mil.

AstraZeneca Pharma India's quarterly Other Stockholders Equity declined from Sep. 2025 (₹7,940 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹8,678 Mil).

AstraZeneca Pharma India's annual Other Stockholders Equity increased from Mar. 2024 (₹1,288 Mil) to Mar. 2025 (₹1,326 Mil) and increased from Mar. 2025 (₹1,326 Mil) to Mar. 2026 (₹8,678 Mil).

AstraZeneca Pharma India Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Other Stockholders Equity Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,274.30 1,280.50 1,287.70 1,326.30 8,677.90

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,326.30 0.00 7,940.00 0.00 8,677.90
NSE:ASTRAZEN
94GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹8,678 Mil mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Other Stockholders Equity of ₹8,678 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's Other Stockholders Equity too high?
AstraZeneca Pharma India's current Other Stockholders Equity is ₹8,678 Mil. Overall, AstraZeneca Pharma India has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Other Stockholders Equity compare to ZTS and UTHR?
AstraZeneca Pharma India's Other Stockholders Equity of ₹8,678 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current Other Stockholders Equity is ₹8,678 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,925.42, compared to a current price of ₹8,310.50 — trading 23.9% below its estimated fair value. The current Other Stockholders Equity is ₹8,678 Mil. AstraZeneca Pharma India's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Other Stockholders Equity is ₹8,678 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,310.50 is trading 23.9% below its estimated GF Value™ of ₹10,925.42. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • Other Stockholders Equity: ₹8,678 Mil
  • GF Value™: ₹10,925.42 vs. price of ₹8,310.50 (23.9% below fair value)
  • GF Score™: 94/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
94GF Score

Get the complete analysis for NSE:ASTRAZEN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,310.50
Price
₹10,925.42
GF Value